A Phase 1/2 Multi-center Investigation of ABI-009 (Nab-rapamycin) in Combination With FOLFOX and Bevacizumab as First-line Therapy in Patients With Advanced or Metastatic Colorectal Cancer
Phase of Trial: Phase I/II
Latest Information Update: 11 Dec 2019
Price : $35 *
At a glance
- Drugs Sirolimus (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors AADi
- 07 Dec 2019 Planned End Date changed from 1 Apr 2021 to 1 Dec 2021.
- 07 Dec 2019 Planned primary completion date changed from 1 Apr 2020 to 1 Dec 2020.
- 20 Feb 2019 Planned number of patients changed from 43 to 58.